Bromocriptine use and the risk of valvular heart disease.
Identifieur interne : 001F38 ( PubMed/Corpus ); précédent : 001F37; suivant : 001F39Bromocriptine use and the risk of valvular heart disease.
Auteurs : Louis C S. Tan ; Kenneth K C. Ng ; Wing-Lok Au ; Raymond K K. Lee ; Yiong-Huak Chan ; Nigel C K. TanSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.
English descriptors
- KwdEn :
- Aged, Aortic Valve Insufficiency (chemically induced), Aortic Valve Insufficiency (diagnosis), Aortic Valve Insufficiency (genetics), Bromocriptine (administration & dosage), Bromocriptine (adverse effects), Dopamine Agonists (administration & dosage), Dopamine Agonists (adverse effects), Dose-Response Relationship, Drug, Echocardiography, Doppler, Female, Heart Valve Diseases (chemically induced), Heart Valve Diseases (diagnosis), Heart Valve Diseases (genetics), Humans, Male, Mitral Valve Insufficiency (chemically induced), Mitral Valve Insufficiency (diagnosis), Mitral Valve Insufficiency (genetics), Parkinson Disease, Receptor, Serotonin, 5-HT2B (drug effects), Receptor, Serotonin, 5-HT2B (genetics), Risk Factors, Severity of Illness Index, Tricuspid Valve Insufficiency (chemically induced), Tricuspid Valve Insufficiency (diagnosis), Tricuspid Valve Insufficiency (genetics).
- MESH :
- chemical , administration & dosage : Bromocriptine, Dopamine Agonists.
- chemical , adverse effects : Bromocriptine, Dopamine Agonists.
- chemically induced : Aortic Valve Insufficiency, Heart Valve Diseases, Mitral Valve Insufficiency, Tricuspid Valve Insufficiency.
- diagnosis : Aortic Valve Insufficiency, Heart Valve Diseases, Mitral Valve Insufficiency, Tricuspid Valve Insufficiency.
- chemical , drug effects : Receptor, Serotonin, 5-HT2B.
- genetics : Aortic Valve Insufficiency, Heart Valve Diseases, Mitral Valve Insufficiency, Receptor, Serotonin, 5-HT2B, Tricuspid Valve Insufficiency.
- Aged, Dose-Response Relationship, Drug, Echocardiography, Doppler, Female, Humans, Male, Parkinson Disease, Risk Factors, Severity of Illness Index.
Abstract
It has been reported that patients on pergolide and carbergoline have an increased risk of developing valvular heart disease. It is uncertain if bromocriptine, an ergot-derived dopamine agonist (DA) with partial 5-HT(2B) activity, is associated with a similar risk. We assessed the frequency of valvular heart disease in Parkinson's disease (PD) patients on bromocriptine compared to pergolide and a control group of PD patients who had not been treated on any DA. Seventy-two PD patients on bromocriptine, 21 patients on pergolide, and 47 control PD patients were recruited. Transthoracic echocardiographic studies were performed and reviewed by a blinded cardiologist. The risk for the bromocriptine group to develop any abnormal valvular regurgitation was 3.32 (adjusted OR, 95% CI: 1.11-9.92, P = 0.03) compared to controls, whereas the risk for the pergolide group was 3.66 (adjusted OR, 95% CI: 1.22-10.97, P = 0.02). When cumulative dose of bromocriptine was analyzed by quartiles, patients with a greater exposure to bromocriptine had significantly higher risk of developing both mild and moderate-severe regurgitations (P for trend, 0.005 and 0.019, respectively). This study demonstrated that bromocriptine use was associated with an increased risk of developing valvular heart disease, which occurred in a cumulative dose-dependent manner.
DOI: 10.1002/mds.22228
PubMed: 18989898
Links to Exploration step
pubmed:18989898Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bromocriptine use and the risk of valvular heart disease.</title><author><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C S" last="Tan">Louis C S. Tan</name><affiliation><nlm:affiliation>Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute, Singapore. louis_tan@nni.com.sg</nlm:affiliation></affiliation></author><author><name sortKey="Ng, Kenneth K C" sort="Ng, Kenneth K C" uniqKey="Ng K" first="Kenneth K C" last="Ng">Kenneth K C. Ng</name></author><author><name sortKey="Au, Wing Lok" sort="Au, Wing Lok" uniqKey="Au W" first="Wing-Lok" last="Au">Wing-Lok Au</name></author><author><name sortKey="Lee, Raymond K K" sort="Lee, Raymond K K" uniqKey="Lee R" first="Raymond K K" last="Lee">Raymond K K. Lee</name></author><author><name sortKey="Chan, Yiong Huak" sort="Chan, Yiong Huak" uniqKey="Chan Y" first="Yiong-Huak" last="Chan">Yiong-Huak Chan</name></author><author><name sortKey="Tan, Nigel C K" sort="Tan, Nigel C K" uniqKey="Tan N" first="Nigel C K" last="Tan">Nigel C K. Tan</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="doi">10.1002/mds.22228</idno><idno type="RBID">pubmed:18989898</idno><idno type="pmid">18989898</idno><idno type="wicri:Area/PubMed/Corpus">001F38</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Bromocriptine use and the risk of valvular heart disease.</title><author><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C S" last="Tan">Louis C S. Tan</name><affiliation><nlm:affiliation>Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute, Singapore. louis_tan@nni.com.sg</nlm:affiliation></affiliation></author><author><name sortKey="Ng, Kenneth K C" sort="Ng, Kenneth K C" uniqKey="Ng K" first="Kenneth K C" last="Ng">Kenneth K C. Ng</name></author><author><name sortKey="Au, Wing Lok" sort="Au, Wing Lok" uniqKey="Au W" first="Wing-Lok" last="Au">Wing-Lok Au</name></author><author><name sortKey="Lee, Raymond K K" sort="Lee, Raymond K K" uniqKey="Lee R" first="Raymond K K" last="Lee">Raymond K K. Lee</name></author><author><name sortKey="Chan, Yiong Huak" sort="Chan, Yiong Huak" uniqKey="Chan Y" first="Yiong-Huak" last="Chan">Yiong-Huak Chan</name></author><author><name sortKey="Tan, Nigel C K" sort="Tan, Nigel C K" uniqKey="Tan N" first="Nigel C K" last="Tan">Nigel C K. Tan</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aortic Valve Insufficiency (chemically induced)</term><term>Aortic Valve Insufficiency (diagnosis)</term><term>Aortic Valve Insufficiency (genetics)</term><term>Bromocriptine (administration & dosage)</term><term>Bromocriptine (adverse effects)</term><term>Dopamine Agonists (administration & dosage)</term><term>Dopamine Agonists (adverse effects)</term><term>Dose-Response Relationship, Drug</term><term>Echocardiography, Doppler</term><term>Female</term><term>Heart Valve Diseases (chemically induced)</term><term>Heart Valve Diseases (diagnosis)</term><term>Heart Valve Diseases (genetics)</term><term>Humans</term><term>Male</term><term>Mitral Valve Insufficiency (chemically induced)</term><term>Mitral Valve Insufficiency (diagnosis)</term><term>Mitral Valve Insufficiency (genetics)</term><term>Parkinson Disease</term><term>Receptor, Serotonin, 5-HT2B (drug effects)</term><term>Receptor, Serotonin, 5-HT2B (genetics)</term><term>Risk Factors</term><term>Severity of Illness Index</term><term>Tricuspid Valve Insufficiency (chemically induced)</term><term>Tricuspid Valve Insufficiency (diagnosis)</term><term>Tricuspid Valve Insufficiency (genetics)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bromocriptine</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Bromocriptine</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Aortic Valve Insufficiency</term><term>Heart Valve Diseases</term><term>Mitral Valve Insufficiency</term><term>Tricuspid Valve Insufficiency</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Aortic Valve Insufficiency</term><term>Heart Valve Diseases</term><term>Mitral Valve Insufficiency</term><term>Tricuspid Valve Insufficiency</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptor, Serotonin, 5-HT2B</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Aortic Valve Insufficiency</term><term>Heart Valve Diseases</term><term>Mitral Valve Insufficiency</term><term>Receptor, Serotonin, 5-HT2B</term><term>Tricuspid Valve Insufficiency</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Echocardiography, Doppler</term><term>Female</term><term>Humans</term><term>Male</term><term>Parkinson Disease</term><term>Risk Factors</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">It has been reported that patients on pergolide and carbergoline have an increased risk of developing valvular heart disease. It is uncertain if bromocriptine, an ergot-derived dopamine agonist (DA) with partial 5-HT(2B) activity, is associated with a similar risk. We assessed the frequency of valvular heart disease in Parkinson's disease (PD) patients on bromocriptine compared to pergolide and a control group of PD patients who had not been treated on any DA. Seventy-two PD patients on bromocriptine, 21 patients on pergolide, and 47 control PD patients were recruited. Transthoracic echocardiographic studies were performed and reviewed by a blinded cardiologist. The risk for the bromocriptine group to develop any abnormal valvular regurgitation was 3.32 (adjusted OR, 95% CI: 1.11-9.92, P = 0.03) compared to controls, whereas the risk for the pergolide group was 3.66 (adjusted OR, 95% CI: 1.22-10.97, P = 0.02). When cumulative dose of bromocriptine was analyzed by quartiles, patients with a greater exposure to bromocriptine had significantly higher risk of developing both mild and moderate-severe regurgitations (P for trend, 0.005 and 0.019, respectively). This study demonstrated that bromocriptine use was associated with an increased risk of developing valvular heart disease, which occurred in a cumulative dose-dependent manner.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">18989898</PMID><DateCreated><Year>2009</Year><Month>03</Month><Day>03</Day></DateCreated><DateCompleted><Year>2009</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Bromocriptine use and the risk of valvular heart disease.</ArticleTitle><Pagination><MedlinePgn>344-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22228</ELocationID><Abstract><AbstractText>It has been reported that patients on pergolide and carbergoline have an increased risk of developing valvular heart disease. It is uncertain if bromocriptine, an ergot-derived dopamine agonist (DA) with partial 5-HT(2B) activity, is associated with a similar risk. We assessed the frequency of valvular heart disease in Parkinson's disease (PD) patients on bromocriptine compared to pergolide and a control group of PD patients who had not been treated on any DA. Seventy-two PD patients on bromocriptine, 21 patients on pergolide, and 47 control PD patients were recruited. Transthoracic echocardiographic studies were performed and reviewed by a blinded cardiologist. The risk for the bromocriptine group to develop any abnormal valvular regurgitation was 3.32 (adjusted OR, 95% CI: 1.11-9.92, P = 0.03) compared to controls, whereas the risk for the pergolide group was 3.66 (adjusted OR, 95% CI: 1.22-10.97, P = 0.02). When cumulative dose of bromocriptine was analyzed by quartiles, patients with a greater exposure to bromocriptine had significantly higher risk of developing both mild and moderate-severe regurgitations (P for trend, 0.005 and 0.019, respectively). This study demonstrated that bromocriptine use was associated with an increased risk of developing valvular heart disease, which occurred in a cumulative dose-dependent manner.</AbstractText><CopyrightInformation>(c) 2008 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Louis C S</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute, Singapore. louis_tan@nni.com.sg</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Kenneth K C</ForeName><Initials>KK</Initials></Author><Author ValidYN="Y"><LastName>Au</LastName><ForeName>Wing-Lok</ForeName><Initials>WL</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Raymond K K</ForeName><Initials>RK</Initials></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Yiong-Huak</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Nigel C K</ForeName><Initials>NC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044403">Receptor, Serotonin, 5-HT2B</NameOfSubstance></Chemical><Chemical><RegistryNumber>3A64E3G5ZO</RegistryNumber><NameOfSubstance UI="D001971">Bromocriptine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001022">Aortic Valve Insufficiency</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001971">Bromocriptine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018491">Dopamine Agonists</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015150">Echocardiography, Doppler</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006349">Heart Valve Diseases</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008944">Mitral Valve Insufficiency</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D044403">Receptor, Serotonin, 5-HT2B</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014262">Tricuspid Valve Insufficiency</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22228</ArticleId><ArticleId IdType="pubmed">18989898</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F38 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001F38 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:18989898
|texte= Bromocriptine use and the risk of valvular heart disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:18989898" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |